Yurisal Akhmad Dany Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia Indonesia
Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia Indonesia
Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia Indonesia
Yurisal Akhmad Dany(1), Ahmad Zulfan Hendri(2), Indrawarman Soerohardjo(3*)
(1) Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia (2) Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia (3) Division of Urology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia (*) Corresponding Author
Abstract
In Indonesia, there are no definite data, but Globocan shows prostate cancer in 5th place in Indonesia in 2018. The aim of this study is to provide in updating database of prostate cancer profile in tertiary hospital in Indonesia. Retrospectively investigated 90 prostate cancer patients at the Sardjito General Hospital Yogyakarta were under follow-up treatment from 2015 to 2020. The medical record was reviewed to find data for the patient’s age, gender, prostate volume, PSA total, testosterone level, hydronephrosis, method of diagnosis, histopathology results, Gleason Scores, ISUP Grade, and Staging TNM. From a total 90 subjects, showed an average age of 67 years (SD=10.4). The level of prostate volume (TAUS), most subjects were >30 cm3 with 73 subjects (81.4%). Of the total subjects, the median of total PSA value for diagnosis is 234.4 (94.4 – 1720.3) ng/mL with the median of total testosterone value at diagnosis is 317 (10 - 384) ng/dL. An equal between biopsy and TURP were used in method of diagnosis and histologic finding consisting of Adenocarcinoma were found in 88 subjects (97.8%) with Gleason score > 7 in 69 subject (69.6%) and ISUP Grade 5 in 59 subject (65.6%). The staging T1c was found in 43 subjects (47.8%) and M staging with metastasis stage was found in 55 subjects (61.1%). In contrast with developed country, this study shows that most Indonesian prostate cancer patients are diagnosed in metastatic stage with higher PSA level and ISUP grade. Further encouragement in prostate cancer screening for men with symptoms or risk factor should be considered to find more cases in lower stages for better prognosis and survival rate.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394-424. https://doi.org/10.3322/caac.21492 2.Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6):1079-92. https://doi.org/10.1016/j.eururo.2012.02.054 3.Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: A global context. Salud Publica Mex 2016; 58(2):104-17. https://doi.org/10.21149/spm.v58i2.7779 4.Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, Wong SYS, et al. Global Incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 2016; 70(5):862-74. https://doi.org/10.1016/j.eururo.2016.05.043 5.Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr 2012; (45):152-6. https://doi.org/10.1093/jncimonographs/lgs035 6.Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The New human kallikrein gene family : implications in carcinogenesis. Trends Endocrinol Metab 2000;11(2):54-60. https://doi.org/10.1186/1755-8794-4-76 7.Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987; 214(2):317-22. https://doi.org/10.1186/1755-8794-4-76 8.Mccormack RT, Rittenhouse HG, Finaly JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family a new era. Urology 1995; 45(5):729-44 . https://doi.org/10.1016/s0090-4295(99)80076-4 9.Henttu P, Liao S, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992; 130(2):766-72. https://doi.org/10.1006/cbir.2000.0433 10.Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19(2):175-81. https://doi.org/10.1007/s10552-007-9083-8 11.World Health Organization. Indonesia Source GLOBOCAN 2018. Int Agency Res Cancer. 2019; 256:1–2. https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf 12.Indonesian Society of Urologic Oncology (ISUO) meeting. 2011. Unpublished data. 13.Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8):737-46. https://doi.org/10.1016/j.urolonc.2016.12.021 14.Broeck T, Van den. European Association of Urology 2020 EAU Guidelines. https://uroweb.org/guideline/prostate-cancer/ 15.Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56(6):1021-4. https://doi.org/10.1016/s0090-4295(00)00793-7 16.Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, et al. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 2017; 13(3):1949-57. https://doi.org/10.3892/ol.2017.5616 17.Gyeong-Ju A. The relationship between levels of serum testosterone and prostate-specific antigen in healthy men: an integrative review. Journal of Korean Biological Nursing Science 2020; 22(2):71-80. https://doi.org/10.7586/jkbns.2020.22.2.71
* Corresponding Author
https://doi.org/10.19106/JMedSci005303202104 
Abstract views : 1217
| 
views : 1517
